Meulien, Pierre
Funding for this research was provided by:
Innovative Medicines Initiative
Article History
First Online: 28 January 2021
Competing interests
: P.M. is the Executive Director of the IMI, which is supported by the European Union’s Horizon 2020 Research and Innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The opinions expressed in this article do not necessarily reflect the positions and opinions of the European Commission or EFPIA.
Free to read: This content has been made available to all.